Gastric Balloons System Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product ( Single Intra Gastric Balloon,Double Intra Gastric Balloon, Triple Intra Gastric Balloon), By Filling Material (Saline Filling, Gas Filling), By Route Of Administration (Endoscopy, Swallowable), By End User (Hospitals, Bariatric Clinics, Ambulatory Surgical Centers) and Region

Gastric Balloons System Market Size was valued at US$ 88.85 million in 2023 and is poised to grow at a significant CAGR of 9.7% from 2024-2030. The gastric balloon system is an innovative non-surgical weight loss procedure in which physicians temporarily places the gastric balloon in the stomach. Gastric balloon system will be placed in the stomach using endoscopy through oesophagus and some of the products are in swallowable capsule form. With the help of gastric balloons, patient feels fluffiness and it enables to reduce the weight. Gastric balloon system market is used for patients only when diet and exercise have failed in reducing weight and surgery is not wanted or recommended to the patient.  According to WHO Global Health Observatory data, 2014 more than 1.9Bn people worldwide and nearly one-quarter of children, adolescents in developed countries are overweight or obese.

At least 2.8 Mn people each year die as result of overweight or obese and half of the world’s population may be subjected to obesity by 2030. Moreover, increase in the awareness about the consequences related to obesity and chances of getting the other chronic diseases, patients are preferring to lose weight. Apart from aforementioned factors, advances in gastric balloon technology led to safer and cost-effective procedure over the surgical procedures. Along with this, short hospital stay, reducing recovery time, expected to prompt healthcare professionals to choose the gastric balloon systems over other bariatric procedures. However, the adverse events associated with gastric balloon systems such as inflation of balloon, pain, swelling, vomiting, and chances of getting acute pancreatitis are becoming as restrains for the market.  

Key Developments:

• On Sept 06, 2022: Allurion, a company dedicated to ending obesity, has launched the Allurion Swallowable Capsule in India - the only medical weight-loss device fully approved by the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority of India overseen by the Ministry of Health & Family Welfare’s Directorate General of Health Services.
• On October 23, 2024: Allurion Technologies, Inc., a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for the Allurion Balloon. The Company expects to file the fourth and final module of the PMA containing the clinical data from its AUDACITY trial early next year.